Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.86 USD
0.00 (0.00%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $26.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
ALKS 26.86 0.00(0.00%)
Will ALKS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
Here's Why Alkermes (ALKS) is a Strong Growth Stock
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Alkermes (ALKS) is a Strong Growth Stock
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Why Alkermes (ALKS) is a Top Value Stock for the Long-Term
Other News for ALKS
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Alkermes initiates Vibrance-2 Phase 2 study evaluating ALKS 2680
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Fulcrum appoints Isabel Kalofonos as CCO
IXJ: Healthcare Sector Dashboard For August